Bayer's Shareholder Meeting Sets Stage for a Pivotal May

Bayer's shareholder meeting votes on a minimal dividend and new board amid financial strain and legal woes, while its Parkinson's gene therapy gains regulatory momentum ahead of Q1 results.

Bayer AG enters a critical communications blackout ahead of its first-quarter results in May, but not before shareholders convene for a virtual annual meeting on April 24. The gathering will vote on a skeletal dividend and a refreshed supervisory board, setting the tone for a month where pipeline hopes collide with persistent financial and legal realities.

The proposed dividend of a mere 0.11 euros per share underscores the company's strained finances. Management is prioritizing balance sheet repair, heavily burdened by provisions for ongoing litigation. This fiscal caution is reflected in the stock's recent performance; shares fell over 3% on Tuesday to 39.97 euros, pushing the Relative Strength Index (RSI) to an oversold reading of 23.3. Despite an impressive near-85% gain over the past year, the current pullback has taken the stock further from its annual high.

A key item on the meeting's agenda is a supervisory board reshuffle. Long-serving members Paul Achleitner and Colleen Goggins are stepping down. Their proposed replacements bring specific industry expertise: Marcel Smits, former Asia chief for US agribusiness giant Cargill, and Alfred Stern, the current CEO of Austrian energy group OMV, who offers chemistry and energy sector experience.

Operationally, Bayer reports it is on track. For 2025, the company posted a slight revenue increase to approximately 45.6 billion euros. It targets currency-adjusted sales of 45 to 47 billion euros for the current year. A new organizational model is expected to contribute positively to earnings by two billion euros, and the company states it has already factored potential US import tariffs on medicines into its plans.

Beyond the balance sheet, Bayer's pharmaceutical pipeline is generating notable regulatory momentum. AskBio, its wholly-owned subsidiary, has submitted its commercially-ready manufacturing process for the Parkinson's gene therapy Ametefgene Parvec (AB-1005) to the FDA. This allows the US Phase II REGENERATE-PD study to proceed with material from Viralgen's commercial-scale plant. The therapy has already received Japan's SAKIGAKE designation and the FDA's RMAT classification, both designed to significantly accelerate the regulatory pathway.

Yet, the shadow of litigation remains a dominant counterweight. The stock's recent decline is partly attributed to a provisional court approval in Missouri for the $7.25 billion Roundup settlement. The company's adjusted EBITDA outlook for 2026, projected between 9.6 and 10.1 billion euros, signals at best a stagnation. Goldman Sachs maintains a constructive view, reiterating a buy rating with a 54-euro price target yesterday. The bank sees twin catalysts for a re-rating: the containment of legal disputes and progress in the pharma pipeline.

All eyes now turn to May for the next significant catalyst. On May 12, Bayer will release its first-quarter figures, with analysts expecting earnings per share of 2.22 euros on average. This report will be scrutinized for evidence of a promised recovery in the pharmaceuticals division. By the end of the decade, management aims to achieve an operating margin of around 30 percent. The coming weeks will test whether Bayer's narrative can successfully pivot from legal liability to therapeutic innovation.